Brief: Innate Pharma Says AstraZeneca Initiated 2nd Phase 3 Monalizumab Trial
29/04/2022 06:04
April 29 (Reuters) - Innate Pharma SA IPH.PA :
* FIRST PATIENT DOSED IN MONALIZUMAB PHASE 3 LUNG CANCER
CLINICAL
TRIAL TRIGGERS $50M PAYMENT FROM ASTRAZENECA
* SECOND PHASE 3 MONALIZUMAB TRIAL NOW INITIATED BY
ASTRAZENECA
Source text for Eikon: ID:nBw1q4ZrPa
Further company coverage: IPH.PA
(Gdansk Newsroom)
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch